pharma · cystic fibrosis · Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
Théa Pharma Ireland
Verona Pharma Ireland Limited
Verona Pharma Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include cystic fibrosis, Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive), multifocal spasticit
Company details
- Status
- Public
- HQ
- Castlebar, IE
- Founded
- 2018
- Employees
- 19
- Programs
- 11
- Drugs
- 42
- Patents
- 0
PASSION
Phase 2 · small molecule · Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy
PASSION for Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy is a Phase 2 program (small_molecule) at Verona Pharma Ireland Limited with 1 ClinicalTrials.gov record(s).
Internal code PASSION
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Verona Pharma Ireland Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy
- Status
- active
- Trials
- 1